EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
Top Stories Tamfitronics HONG KONG, Sept 11, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 […]